Editor’s highlights from the Journal of Comparative Effectiveness Research – March 2024
In this monthly column, I share some of my Editor’s highlights from the latest issue of the Journal of Comparative Effectiveness Research (JCER), partner journal of The Evidence Base.
Welcome to my monthly Editor’s highlights from the Journal of Comparative Effectiveness Research (JCER), with my picks from the March issue (Volume 13, Issue 3). This month’s content includes the latest market access-focused Industry Update from Sreeram Ramagopalan and colleagues, along with a Protocol article for a study in endometrial cancer and original research comparing treatments for migraine.
Access in all areas? A round up of developments in market access and health technology assessment: part 3
In the latest in their popular Industry Update series, Ramagopalan et al. (Lane Clark & Peacock LLP, London, UK) explore some of the key recent events in market access, including the UK’s voluntary scheme for branded medicines pricing, access and growth (VPAG); the first drugs funded by the Innovative Medicines Fund in the UK and the Direct Access Scheme in France; and the new Institute for Clinical and Economic Review (ICER) value assessment framework in the USA.
You may also be interested in:
- ICER revises its value assessment framework, but is it enough?
- World Evidence, Pricing and Access (EPA) Congress 2024: Navigating the conference program
Study Protocol for the Social Interventions for Support During Treatment for Endometrial Cancer and Recurrence (SISTER) study: a community engaged national randomized trial
The SISTER study, which focuses on addressing social isolation among Black women with high-risk endometrial cancer in the USA, aims to compare different support interventions to see if they improve treatment completion compared to usual care. Here, authors Doll et al. (University of Washington, WA, USA) describe the protocol for the study, which is expected continue enrollment through June 2025, with primary analysis scheduled for completion in November 2025.
Comparative effectiveness of erenumab versus rimegepant for migraine prevention using matching-adjusted indirect comparison
Finally, in a new study, Ronan Mahon and colleagues (Novartis Ireland Limited) compare the efficacy of erenumab with rimegepant as a treatment for prevention of episodic and chronic migraine – the second leading cause of disability affecting over 1 billion people worldwide. The researchers conducted a matching-adjusted indirect comparison to assess various efficacy outcomes, including changes in monthly migraine days, changes in Migraine-Specific Quality of Life Questionnaire role function, and change in disability.
In addition to my Editor’s highlights, you can read the full March issue of JCER here, where all the articles are freely available to read. The journal welcomes pre-submission enquiries, so do get in touch if you would be interested in contributing.
